The original version of the paper [1] reports that “This ACTIVE I study was supported by Pfizer” (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer. Therefore, we would like to correct the wording to read: “This ACTIVE I study was supported by Bristol-Myers Squibb and Sanofi-Aventis”. The authors apologize for any inconvenience this may have caused to the readers of this journal.
Reference
- 1.Kikuchi K., Tancharoen S., Ito T., Morimoto-Yamashita Y., Miura N., Kawahara K.-I., Maruyama I., Murai Y., Tanaka E. Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci. 2013;14:18899–18924. doi: 10.3390/ijms140918899. [DOI] [PMC free article] [PubMed] [Google Scholar]